SEROLOGICAL COLLAGEN BIOMARKERS CAN DIFFERENTIATE PATIENTS WITH PSORIASIS FROM PSORIATIC ARTHRITIS
Abstract: OP0031
Authors: Groen SS et al.
Key content:
Collagens are major proteins of cartilage and bones and other tissues. Inflammation may lead to collagen degradation and release of fragments into the circulation. The aim of the present study was to identify serum biomarkers that may allow differentiation of patients with PsO with or without PsA.
87 PsO patients underwent rheumatologic assessment to exclude and 99 PsA patients were recruited, all of comparable mean age (42 + 12.2 versus 45.9 + 12.47 and 44 and 49% females). Anabolic and catabolic extracellular matrix biomarkers such as PRO-C3, PRO-C4, PRO-6, C1M, C3M, C4M, C6M) were determined. Patients with PsA presented higher levels of C1M, C3M, C6M and PRO-C6 compared to PsO (p<0.046), while other biomarkers did not show any differences. C1M and C6M were able to separate between PsO and PsA with an AUROC=0.6277 (p=0.0027) and AUROC=0.6446 (p=0.001), respectively.
Relevance:
Nearly 25% of PsO patients may have concomitant PsA. Delayed diagnosis of PsA is associated with joint damage and functional disability. Various strategies ranging from early referrals to rheumatologists or implementing joint ultrasound within dermatologist departments have been discussed to allow early identification of these patients. Serum biomarkers, mainly the catabolic collagen degradation markers C1M and C6M may allow to identify inflammatory musculoskeletal involvement in PsO patients. Whether or not these markers are suitable for longterm follow-up of patients and whether different treatments may affect these markers still need to be explored.
